FOXO3 and leukemia: Knockdown of FOXO3 results in increased CSC self-renewal capacity in prostate, glioblastoma, ovarian, breast, liver, and colorectal cancer [47–51]; in contrast leukemia-initiating cells need FOXO3 for stem cell maintenance [52, 53].